Date: 2017-09-28
Type of information: Granting of a patent
Product name: remimazolam
Compound: remimazolam
Therapeutic area: CNS diseases
Action mechanism:
- benzodiazepine derivative. Remimazolam is a short-acting general anaesthetic/sedative. Sedatives are used, for example, in endoscopic procedures such as colonoscopies. After intravenous administration remimazolam rapidly induces the desired sedation. Importantly, this sedative effect quickly disappears. This rapid offset of the effect of the substance is due to its metabolism by tissue esterase enzymes that are widely distributed throughout the body. Remimazolam is being developed as a sedative agent for day case procedures (procedural sedation) as well as for the induction and maintenance of anaesthesia. It could also be used as a sedative for patients in the Intensive Care Unit (ICU).
Company: Paion (Germany)
Disease:
Latest news:
Patents:
- • On September 28, 2017, Paion announced that a formulation patent for remimazolam has been granted in the EU by the European Patent Office. The patent named "Compositions Comprising Short-Acting Benzodiazepines" will be published under Patent No. 2852389. This patent relates to stable preparations of remimazolam and related compounds. This represents an important prerequisite for the efficient manufacture and distribution of this innovative drug. Based on the careful selection of excipients and manufacturing conditions our research efforts enabled patent claims further extending the exclusivity of this highly advantageous remimazolam formulation in the European market. The patent will expire in May 2033.
Submission of marketing authorization application USA :
Submission of marketing authorization application UE:
Withdrawal of marketing authorization application USA:
Withdrawal of marketing authorization application UE:
US authorization:
UE authorization:
Favourable opinion UE:
Favourable opinion USA:
Orphan status USA:
Orphan status UE:
Pediatric exclusivit _USA:
Pediatric exclusivity UE:
OTC status:
Other news:
Is general: Yes
